The effect of ivabradine therapy on dilated cardiomyopathy patients with congestive heart failure: a systematic review and meta-analysis

Juntao Yang; Tingting Lv; Jiedong Zhou; Hui Lin; Bingjie Zhao; Haifei Lou; Hanxuan Liu; Tao Zhang; Hangyuan Guo; Jufang Chi

doi:10.3389/fcvm.2023.1149351

The effect of ivabradine therapy on dilated cardiomyopathy patients with congestive heart failure: a systematic review and meta-analysis

Front Cardiovasc Med. 2023 Oct 17:10:1149351. doi: 10.3389/fcvm.2023.1149351. eCollection 2023.

Authors

Juntao Yang^#¹, Tingting Lv^#¹, Jiedong Zhou^#¹, Hui Lin², Bingjie Zhao¹, Haifei Lou³, Hanxuan Liu¹, Tao Zhang¹, Hangyuan Guo¹, Jufang Chi⁴

Affiliations

¹ School of Medicine, Shaoxing University, Shaoxing, China.
² Ningbo Medical Center Lihuili Hospital (Lihuili Hospital Affiliated to Ningbo University), Ningbo, China.
³ Department of Cardiology, Shaoxing People's Hospital, Shaoxing, China.
⁴ Department of Cardiology, Zhuji People's Hospital, Zhuji, China.

^# Contributed equally.

Abstract

Background: Ivabradine improves cardiac function in patients with heart failure, but its effect on dilated cardiomyopathy (DCM) remains unclear. We performed a systematic review and meta-analysis to study the efficacy and potential mechanisms of ivabradine's effect on cardiac function and prognosis in patients with DCM.

Methods: We searched PubMed, Cochrane Library, Embase, Web of Science, and four registers through September 28, 2022. All controlled trials of ivabradine for the treatment of DCM with congestive heart failure were included. Articles were limited to English, with the full text and necessary data available. We performed random- or fixed effects meta-analyses for all included outcome measures and compared the effect sizes for outcomes in patients treated with and without ivabradine. The quality of the studies was assessed using the Cochrane risk-of-bias tool for randomized trials (RoB2.0).

Findings: Five trials with 357 participants were included. The pooled risk ratio was 0.48 [95% confidence interval (CI) (0.18, 1.25)] for all-cause mortality and 0.38 [95% CI (0.12, 1.23)] for cardiac mortality. The pooled mean difference was -15.95 [95% CI (-19.97, -11.92)] for resting heart rate, 3.96 [95% CI (0.99, 6.93)] for systolic blood pressure, 2.93 [95% CI (2.09, 3.77)] for left ventricular ejection fraction, -5.90 [95% CI (-9.36, -2.44)] for left ventricular end-systolic diameter, -3.41 [95% CI (-5.24, -1.58)] for left ventricular end-diastolic diameter, -0.81 [95% CI (-1.00, -0.62)] for left ventricular end-systolic volume, -0.67 [95% CI (-0.86, -0.48)] for left ventricular end-diastolic volume, -11.01 [95% CI (-19.66, -2.35)] for Minnesota Living with Heart Failure score, and -0.52 [95% CI (-0.73, -0.31)] for New York Heart Association class.

Interpretation: Ivabradine reduces heart rate and ventricular volume, and improves cardiac function in patients with DCM, but showed no significant effect on the prognosis of patients.

Keywords: cardiac function; dilated cardiomyopathy; heart failure; heart rate; ivabradine.

Publication types

Review

Grants and funding

This work was funded by The National Natural Science Foundation of China (No. 82174204), Provincial innovative talents training object (60001383) and Special Project of Science and Technology Plan of Shaoxing City, China (2020B33001).